127 related articles for article (PubMed ID: 31445732)
1. Rapid Response to Pembrolizumab in a Critically Ill Mechanically Ventilated Patient with New Diagnosis of NSCLC.
McLoughlin EM; Larner JM; Bergman MP; Stelow EB; Brady K; Lynch AC; Abraham RS; Gentzler RD
J Thorac Oncol; 2019 Sep; 14(9):e193-e195. PubMed ID: 31445732
[No Abstract] [Full Text] [Related]
2. Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer.
Hill A; Gong J; Wilczynski S; Mirza R; Erhunmwunsee L; Salgia R
J Oncol Pract; 2018 Sep; 14(9):569-571. PubMed ID: 30044685
[No Abstract] [Full Text] [Related]
3. Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1-Expressing Non-Small Cell Lung Cancer.
Garcia CA; Dacic S; Villaruz LC
J Thorac Oncol; 2018 Aug; 13(8):e135-e136. PubMed ID: 30049372
[No Abstract] [Full Text] [Related]
4. Effect of pembrolizumab on patients harboring uncommon epidermal growth factor receptor mutations.
Taniguchi Y; Tamiya A; Ishii S; Atagi S
Ann Oncol; 2018 May; 29(5):1331-1333. PubMed ID: 29522162
[No Abstract] [Full Text] [Related]
5. [Prolonged response with paclitaxel after immunotherapy by pembrolizumab in lung cancer].
Zapata E; Mennecier B; Leduc C; Chatron E; Quoix E
Rev Pneumol Clin; 2016 Oct; 72(5):300-304. PubMed ID: 27561974
[TBL] [Abstract][Full Text] [Related]
6. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
[TBL] [Abstract][Full Text] [Related]
7. Durable Response After 2 Doses of Pembrolizumab in a Patient With Non-Small-Cell Lung Cancer With an Isolated Brain Metastasis.
Uprety D; Arjyal L; Vallatharasu Y; Bista A; Wittchow RJ; Marinier DE
Clin Lung Cancer; 2019 Sep; 20(5):e552-e554. PubMed ID: 31285178
[No Abstract] [Full Text] [Related]
8. Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer.
Qin A; Street L; Cease K; Viglianti BL; Warren EH; Zhao L; Ramnath N
Clin Lung Cancer; 2017 Sep; 18(5):559-564. PubMed ID: 28366756
[TBL] [Abstract][Full Text] [Related]
9. Consolidation therapy after concurrent radiochemotherapy? Still unclear who may potentially benefit!
Jeremic B; Langenhoven L
Lung Cancer; 2013 Dec; 82(3):509. PubMed ID: 24168921
[No Abstract] [Full Text] [Related]
10. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.
Dang TO; Ogunniyi A; Barbee MS; Drilon A
Expert Rev Anticancer Ther; 2016; 16(1):13-20. PubMed ID: 26588948
[TBL] [Abstract][Full Text] [Related]
11. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab Shows Promise for NSCLC.
Cancer Discov; 2015 Jun; 5(6):572. PubMed ID: 25895920
[TBL] [Abstract][Full Text] [Related]
13. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
Shaverdian N; Lisberg AE; Bornazyan K; Veruttipong D; Goldman JW; Formenti SC; Garon EB; Lee P
Lancet Oncol; 2017 Jul; 18(7):895-903. PubMed ID: 28551359
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US.
Insinga RP; Vanness DJ; Feliciano JL; Vandormael K; Traore S; Burke T
J Med Econ; 2018 Dec; 21(12):1191-1205. PubMed ID: 30188231
[TBL] [Abstract][Full Text] [Related]
15. Is there a standard treatment for locally advanced non-small cell lung cancer?
Buccheri G
Chest; 1996 Apr; 109(4):864-6. PubMed ID: 8635360
[No Abstract] [Full Text] [Related]
16. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
Goldberg SB; Gettinger SN; Mahajan A; Chiang AC; Herbst RS; Sznol M; Tsiouris AJ; Cohen J; Vortmeyer A; Jilaveanu L; Yu J; Hegde U; Speaker S; Madura M; Ralabate A; Rivera A; Rowen E; Gerrish H; Yao X; Chiang V; Kluger HM
Lancet Oncol; 2016 Jul; 17(7):976-983. PubMed ID: 27267608
[TBL] [Abstract][Full Text] [Related]
18. Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
Levy BP; Giaccone G; Besse B; Felip E; Garassino MC; Domine Gomez M; Garrido P; Piperdi B; Ponce-Aix S; Menezes D; MacBeth KJ; Risueño A; Slepetis R; Wu X; Fandi A; Paz-Ares L
Eur J Cancer; 2019 Feb; 108():120-128. PubMed ID: 30654297
[TBL] [Abstract][Full Text] [Related]
19. PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.
Peters S; Kerr KM; Stahel R
Cancer Treat Rev; 2018 Jan; 62():39-49. PubMed ID: 29156447
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab Outperforms Docetaxel for NSCLC.
Leslie M
Cancer Discov; 2016 Mar; 6(3):223. PubMed ID: 26811324
[No Abstract] [Full Text] [Related]
[Next] [New Search]
